Meet the Leaders

Biological Modeling Specialty Section

Richard A. Corley, Ph.D., President

Dr. Corley is currently a Laboratory Fellow in the Biological Monitoring & Modeling Group, Pacific Northwest National Laboratory (PNNL), Richland, WA. He received his Ph.D. in Environmental Toxicology from the University of Illinois in 1985 before joining The Dow Chemical Company’s Toxicology Research Laboratory; initially as a Postdoctoral Fellow in physiologically based pharmacokinetic (PBPK) modeling, and later as a scientist and group leader of the chronic toxicology and inhalation toxicology research groups. Since joining PNNL in 1996, Dr. Corley has worked to establish a multi-disciplinary research program in pharmacokinetic modeling, 3D imaging, and multi-scale computational toxicology. In that capacity, he continues to serve as a principle investigator or collaborator in government- and industry-sponsored studies to develop, validate, and apply PBPK models and 3D/computational fluid dynamics models of the respiratory system to reduce the uncertainties in target tissue dosimetry for human health risk assessments and improvements in therapeutic interventions. He has served on several committees, working groups, or advisory panels for the NAS, EPA, ILSI, ATSDR, OTA, and CIIT, the editorial board of Toxicol. Appl. Pharmacol., and as an ad hoc reviewer for NIH. He is currently an officer of the Biological Modeling Specialty Section and a member of the Pacific Northwest Association of Toxicologists (PANWAT); he has also served as a past member of SOT’s Program Committee.

Biological Modeling Specialty Section

James V. Bruckner, Ph.D., President-Elect

Dr. Bruckner received his Ph.D. from the University of Michigan. He has held faculty positions are the University of Kansas, the University of Texas Medical School at Houston, and is currently at the University of Georgia (UGA). He was director of UGA’s Graduate Program in Toxicology for 15 years. Dr. Bruckner has served on editorial boards of Toxicology and Applied Pharmacology, Journal of Toxicology and Environmental Health, Toxicology, Chemosphere and International Journal of Toxicology. He is lead author of a chapter entitled “Toxic Effects of Solvents and Vapors” in Casarette and Doull’s Toxicology: The Basic Science of Poisons. His research focus is on the toxicology and toxicokinetics of volatile organic chemicals (VOCs), drug interactions at environmental exposure levels, and toxicokinetic bases for susceptibility of children to insecticides. Dr. Bruckner has served on a variety of expert panels and committees for the U.S. EPA, NIEHS, NASA, Air Force, ATSDR/CDC, FDA and the National Academy of Sciences.

Carcinogenesis Specialty Section

David E. Williams, Ph.D., Vice President-Elect

Dr. Williams (Professor, Environmental and Molecular Toxicology, Senior Scientist, The Linus Pauling Institute, member Environmental Health Sciences Center and Director, Superfund Research Program at Oregon State University) received his B.S. from Reed College and Ph.D.in Biochemistry and Biophysics at Oregon State University (OSU). Following postdoctoral training in Biochemistry at The Medical College of Wisconsin, Dr. Williams returned to OSU and has been on the faculty for 23 years. Dr. Williams’ research area is drug metabolism, carcinogenesis and cancer chemoprevention. He serves as an Associate Editor for TAAP. In addition to the Carcinogenesis Specialty Section, he has served on the following SOT committees: Program (1991-1994); Education (1997-1999); K-12 Education (1997-1998, Chair,1998-1999); Food Safety Specialty Section (Secretary/Treasurer, 1998-2000); and PANWAT (Secretary/Treasurer, 1990-1992; President, 1996-1997). He was a member of AL-TX1 (chair, 2 years) and is currently serving on XNDA. He has authored 165 manuscripts and is the 2009 OSU Alumni Distinguished Professor.

Cardiovascular Specialty Section

Timothy R. Nurkiewicz, Ph.D., President

Dr. Nurkiewicz earned his B.S. from Pennsylvania State University and his M.S. from West Virginia University (WVU). After serving in cardio-pulmonary rehabilitation at Allegheny General Hospital, he returned to WVU and earned his Ph.D. in 1999. Dr. Nurkiewicz performed his post-doctoral training at Texas A&M University in the Department of Medical Physiology. While trained as a microvascular physiologist, he has a broad background ranging from bench top in vitro experiments to clinical interactions. Currently, Dr. Nurkiewicz is an associate professor in the Department of Physiology and Pharmacology at the WVU School of Medicine, where he is also a member of the Center for Cardiovascular and Respiratory Sciences. He serves on the Editorial Board of several toxicology journals; is an ad hoc reviewer for numerous journals and study sections; and participates in various committees and consortiums at University, State and National levels. Dr. Nurkiewicz is a founding member of the Cardiovascular Toxicology Specialty Section.

Comparative and Veterinary Specialty Section

Kathleen L. Gabrielson, D.V.M., Ph.D.., Vice President

Dr. Gabrielson received her Ph.D. in Toxicology from the Johns Hopkins University Bloomberg School of Public Health, and she joined the department of Molecular and Comparative Pathobiology faculty in 2000. She has joint appointments in Environmental Health Sciences, Pathology, Pathobiology and CAAT. She has a supportive faculty role in the Bloomberg School of Public Health NIEHS center and the School of Medicine small animal imaging research program (SAIRP) for histopathology, in vivo imaging and animal model expertise. She serves on the editorial boards of Toxicologic Pathology and Cardiovascular Toxicology. Dr. Gabrielson has a teaching and clinical role in the MCP Comparative Veterinary Medicine post-doctoral training program. She currently serves as an officer for the American College of Veterinary Pathologists and the Society of Toxicology. She is a member of the SOT Continuing Education and K-12 committees and a proctor on the National Exam Committee of the American College of Veterinary Pathologists. She is the author or co-author of more than 60 peer-reviewed papers.

Comparative and Veterinary Specialty Section

Ann F. Hubbs, D.V.M., Ph.D., DACVP., Vice President-Elect

Dr. Hubbs received her D.V.M. from Texas A&M University, an M.S. from Purdue, and a Ph.D. from Colorado State University. She received a certificate of residency in veterinary pathology from Colorado State University, is board eligible in laboratory animal medicine, and is a Diplomate of the American College of Veterinary Pathologists. She has been at the National Institute for Occupational Safety and Health within CDC since 1992. Dr. Hubbs is also an adjunct associate professor at West Virginia University. She has authored or co-authored more than a hundred peer-reviewed publications, which have received numerous awards. Dr. Hubbs is a co-recipient of both the 2008 Bullard-Sherwood Award for Research to Practice and the 2008 National Occupational Research Agenda Partnering Award for Worker Health and Safety. She has received multiple awards for using her scientific skills in responding to important events, such as the anthrax events of 2001, Hurricane Katrina, and monkeypox.

Drug Discovery Toxicology Specialty Section

John W. Davis, II, Ph.D., President

John Davis is presently the director of investigative toxicology at Pfizer, St. Louis, leading a group of scientists in Drug Safety Research and Development responsible for preclinical toxicology screening and mechanistic studies; he has served as the toxicologist on numerous multidisciplinary project teams in both research as well as development; and he served on and led several clinical and preclinical toxicology issue management teams. Prior to joining Pfizer, John was a principal scientist in the Molecular Toxicology Group at Schering-Plough.

Dr. David received a B.S. in pharmacology and toxicology from the University of Wisconsin in 1990 and a Ph.D. in Molecular Toxicology from the Purdue University in 1998. He performed postdoctoral research on the regulation of kinase signaling and gene expression in normal human mammary epithelial cells at the University of New Mexico (mentor Scott Burchiel). John has authored 20 peer-reviewed publications and reviews and has given numerous invited seminars at both scientific meetings as well as academic institutions. He has also co-chaired multiple continuing education courses, symposia, and workshops at both SOT and ACT Annual Meetings including the most recent SOT meeting in which he co-chaired "Strategies to Integrate Systems Biology into In Vitro Screening in Early Nonclinical Safety Assessment." John is a founding/charter member of the Drug Discovery Toxicology Specialty Session. He has also participated in multiple industry-wide consortiums including the nephrotoxicity working group of the ILSI-HESI toxicogenomics group and the Critical Path Initiative's nephrotoxicity biomarkers working group. John is an Adjunct Clinical Full Professor in the College of Pharmacy at the University of New Mexico.

Drug Discovery Toxicology Specialty Section

Kyle Kolaja, Ph.D., DABT, Past President

Kyle Kolaja is currently the Director of Discovery and Investigative Safety at Roche Palo Alto. This group of scientists is responsible for integrating toxicology into the early therapeutic area project teams. The group specifically supports all investigative toxicology aspects of understanding mechanism of toxicity and generating toxicity biomarkers, provides safety pharmacology, toxicogenomics, and genetic toxicology expert guidance, and evaluates new technology for use in early safety assessment. Prior to joining Roche, Dr. Kolaja was Vice President of Chemogenomics and Toxicology at Iconix Pharmaceuticals, a nontraditional biotechnology company that developed a large in vivo and in vitro toxicogenomic reference database. At Iconix, Kyle led the group of scientists responsible for the conduct and interpretation of mechanistic/toxicogenomic studies. The group had collaborations with over 20 pharmaceutical companies as well as the EPA and FDA. Prior to Iconix, Kyle was at Pharmacia Corp. (formerly Searle) where he was a project/platform toxicologist supporting discovery and development projects. He also was the leader of the investigative toxicology group at Skokie and the site director for the laboratory responsible for toxicogenomics. Dr. Kolaja has over 40 peer-reviewed publications and reviews, received his BS from Michigan State University) and his Ph.D. in Toxicology from Indiana University (mentor James Klaunig) and conducted his postdoctoral research at the University of Kansas (mentor Curt Klaassen).

Ethical, Legal, and Social Issues Specialty Section

Melinda Pomeroy-Black, President

Melinda Pomeroy-Black is as currently an Assistant Professor of Biology at LaGrange College (LaGrange, GA), a private liberal arts college with approximately 1000 undergraduate students. She received her BA in Biology from Rhodes College and an MS in Pathology and PhD in Toxicology, both from Virginia Tech. She has been a member of SOT since 2002, serving on the Student Advisory Committee and as the graduate student representative to the National Capital Area Regional Chapter of SOT. Melinda has introduced several courses to the Biology major at LaGrange College, including Toxicology, Immunology and Histology. She is currently teaching a Senior Seminar course in Bioethics. Her research interests include neurotoxicology and alternative species in toxicology research.

Ethical, Legal, and Social Issues Specialty Section

Phil Wexler, B.S., M.L.S., Vice President

Mr. Wexler is a Technical Information Specialist at the National Library of Medicine’s Toxicology and Environmental Health Information Program, where he has been instrumental in developing and enhancing the TOXNET system. He oversees the NLM-SOT project, ToxLearn, spearheaded the development of the World Library of Toxicology, Chemical Safety and Environmental Health, and is a frequent teacher and lecturer on toxicology information systems.

Mr. Wexler is Editor-in-Chief of Elsevier’s Information Resources in Toxicology and the Encyclopedia of Toxicology, and the author of numerous papers. He is currently preparing the Taylor and Francis monograph, Chemicals, Environment, Health: A Global Management Perspective.

A past Chair of the SOT’s World Wide Web Advisory Committee, Mr. Wexler is also a member of the Education and Communications Work Group of the CDC/ATSDR’s National Conversation on Public Health and Chemical Exposure project, and the 2010 recipient of SOT’s Public Communications Award.

Immunotoxicology Specialty Section

Jean Regal, Ph.D., President

Dr. Regal is currently a Professor in the University of Minnesota Medical School Duluth, Department of Pharmacology/Department of Biochemistry & Molecular Biology and is Director of the Academic Health Center Duluth Women’s Mentoring Program. She has been a member of SOT and the Immunotoxicology Specialty Section since 1998. Dr. Regal received her Ph.D. in Pharmacology at the University of Minnesota in Minneapolis, Minnesota and did postdoctoral work in Immunology in the Department of Microbiology/Immunology, Albany Medical College, Albany, New York.

Dr. Regal’s current research is focused on respiratory allergy, especially asthma and she has authored over 50 research articles and reviews in peer-reviewed journals. Her research is focused on mechanistic studies of occupational asthma in animal models, as well as assessment of differences in asthmatic responses with age and gender. She is also a member of the American Association of Immunologists, American Thoracic Society and the American Society of Pharmacology and Experimental Therapeutics. She has served in all the officer positions in the Immunotoxicology Specialty Section as well as the Awards and Program committees for the Northland Chapter of SOT. In addition, in 2006 she participated in the exchange program between the Japanese Society of Immuntoxicology and the Immunotoxicology Specialty Section of SOT. She is currently Associate Editor of the Journal of Immunotoxicology and has served as a reviewer on multiple NIH panels, for the NTP Board of Scientific Counselors and for NIOSH. She participated as an immuntoxicologist on an Institute of Medicine Committee on Health Effects Associated with Exposures Experienced during the Persian Gulf War, in an ECVAM Expert Meeting regarding Progress in the development of New Approaches to the Identification of Respiratory Allergens in 2008, and has also participated in the ICCVAM Peer Panel for review of the Murine LLNA for assessing the allergic contact dermatitis potential of chemicals and products in 1997, 2008, and 2009.

Immunotoxicology Specialty Section

Leigh Ann Burns-Naas, Ph.D., DABT, Vice President

Dr. Burns-Naas received her Ph.D. from the Medical College of Virginia, completed an NIH postdoctoral fellowship at the Mayo Clinic, and is certified by the American Board of Toxicology. Her career has focused primarily on the strategic aspects and design of safety programs to support chemical product development and registration, and to support the clinical development and licensure for small molecules and biotherapeutics. Dr. Burns-Naas maintains an active involvement in Immunotoxicology, including journal editorial board/ad hoc reviewer, teaching at local universities, participation in the HESI ITC, and membership on the Pfizer DSRD Immunotoxicology Council and Biotherapeutics and Biotechnology Network. In addition to her responsibilities with the Immunotoxicology Specialty Section, she is a Councilor for the Women in Toxicology Special Interest Group, founding member of the Biotechnology Specialty Section, former member of the Continuing Education Committee, and current member of the Scientific Program Committee. She is also a Past-President of the American College of Toxicology.

Immunotoxicology Specialty Section

Rodney Dietert, Ph.D., Vice President-Elect

Dr. Dietert is Professor of Immunotoxicology in the Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY. He also serves as a consultant in developmental immunotoxicology for Burleson Research Technologies (BRT-Labs). While at Cornell, Dietert has held the posts of Director of the Institute for Comparative and Environmental Toxicology (ICET), Director of Graduate Studies for the Graduate Field of Immunology, Senior Fellow in the Cornell Center for the Environment and Director of the Cornell Program on Breast Cancer and Environmental Risk Factors (BCERF). Dietert’s research has produced more than 290 publications including over 170 research papers appearing in more than 60 scientific journals. His work was featured on the January 2009 cover of Chemical Research in Toxicology. Most recently, Dietert senior authored the general audience book, Strategies for Protecting Your Child’s Immune System (World Scientific) and edited the text, Immunotoxicity Testing: Methods and Protocols (Springer).

In Vitro and Alternative Methods Specialty Section

David Allen, Ph.D., President

David Allen received his Ph.D. from North Carolina State University. He served as a Study Director and Senior Scientist for Pathology Associates, A Charles River Company before joining the US Food and Drug Administration Center for Drug Evaluation and Research as a Toxicologist. In this capacity, he was responsible for reviewing nonclinical pharmacology and toxicology studies submitted to the Division of Dermatological and Dental Drug Products in support of drug marketing applications. In addition, he served as an FDA representative on the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), Dermal Corrosivity and Irritation Working Group. In 2004, he joined ILS, Inc. as a Toxicologist supporting the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM). He currently serves as the Principal Investigator for the NICEATM support contract where he provides oversight of multiple ongoing evaluations of alternative toxicological test methods submitted for review/evaluation to NICEATM that reduce, refine, or replace the use of animals. Dr. Allen has published numerous articles and abstracts related to the research, development, and validation of alternative test methods in the areas of acute systemic toxicity, dermal and ocular corrosivity and irritation, endocrine disruptors, pyrogenicity, and skin sensitization.

In Vitro and Alternative Methods Specialty Section

Frank A. Barile, Ph.D., Past President

Dr. Barile is Professor of Pharmaceutical Sciences in the Toxicology Division of the Department of Pharmaceutical Sciences, at St. John's University College of Pharmacy and Allied Health Professions, New York.

Dr. Barile received his B.S. in Pharmacy, M.S. in Pharmacology, and Ph.D. in Toxicology (1982) at St. John's University. He completed postdoctoral fellowships in Pulmonary Pediatrics at the Albert Einstein College of Medicine, Bronx, NY, and at the Department of Pathology, Columbia University, NY. In 1984, he was appointed as Assistant Professor in the Department of Health Sciences at City University of NY. Sixteen years later he rejoined St. John's University in the Department of Pharmaceutical Sciences, Toxicology Program, in the College of Pharmacy.

Dr. Barile holds memberships in several professional associations, including the U.S. Society of Toxicology, American Association of University Professors, American Association for the Advancement of Science, American Society of Hospital Pharmacists, New York City Pharmacists Society, New York Academy of Sciences, and New York State Council of Health System Pharmacists, Scientific Advisory Committee for Alternative Toxicological Methods (SACATM, ICCVAM, NIEHS, 2005–2009). He is Past President of the In Vitro and Alternative Methods (IVAM) Specialty Section, 2008–2009, of the U.S. Society of Toxicology.

Dr. Barile has been the recipient of research grants from the National Institutes of Health (NIGMS) for the last 20 years, including awards from the Minority Biomedical Research Support (MBRS) program, the Minority High School Student Research Apprentice (MHSSRAP) program, and AREA program, as well as from private foundations (Alternative Research & Development Foundation, ARDF; International Foundation for Ethical Research, IFER).

Dr. Barile has authored 65 original research papers, as well as three books and one contributed chapter (including the current Informa HealthCare Publishers Principles of Toxicology Testing, 2007, and Clinical Toxicology, 2nd edition, 2009). He was awarded Professor of the Year for the College of Pharmacy, by the University Student Government Association, 2003). Dr. Barile continues fundamental research on the cytotoxic effects of therapeutic drugs and environmental chemicals on cultured human and mouse embryonic stem cells.

Inhalation and Respiratory Specialty Section

Vincent Castranova, Ph.D., Vice President

Vincent Castranova, Ph.D., is the Chief of the Pathology and Physiology Research Branch in the Health Effects Laboratory Division of the National Institute for Occupational Safety and Health, Morgantown, West Virginia. He holds the grade of a CDC Distinguished Consultant. He received the Shepard Lifetime Scientific Achievement Award from CDC in 2008 and the Stokinger Outstanding Achievement in Industrial Toxicology Award from ACGIH in 2009. He is also an adjunct professor in the Department of Basic Pharmaceutical Sciences at West Virginia University, Morgantown, West Virginia and the Department of Environmental and Occupational Medicine at the University of Pittsburgh.

Dr. Castranova received a B.S. in biology from Mount Saint Mary’s College, Emmitsburgh, Maryland in 1970, graduating magna cum laude. He received a Ph.D. in physiology and biophysics in 1974 from West Virginia University, Morgantown, West Virginia before becoming an NIH fellow and research faculty member in the Department of Physiology at Yale University, New Haven, Connecticut. In 1977, Dr. Castranova received a research staff position at the National Institute for Occupational Safety and Health and an adjunct faculty position at West Virginia University, Morgantown, West Virginia. He has served at these institutions since that time.

Dr. Castranova’s research interests have been concentrated in pulmonary toxicology and occupational lung disease. He has been coordinator of the Nanotoxicology Program in NIOSH since its inception in 2005. He has been a co-editor of four books and has co-authored over 470 manuscripts and book chapters.

Mechanisms Specialty Section

Gary O. Rankin, Ph.D., Past President

Dr. Rankin is a Professor and Chair of the Department of Pharmacology, Physiology and Toxicology at Marshall University. He has co-authored or authored 130 publications and his area of research focuses on renal toxicology.

He received a bachelor’s degree in Chemistry in 1972 from the University of Arkansas and received his doctorate degree in Medicinal Chemistry from the University of Mississippi in 1976.

Mixtures Specialty Section

Michael Dourson, Ph.D., DABT, ATS, Vice President-Elect

Dr. Dourson is the President of the non-profit group Toxicology Excellence for Risk Assessment (TERA). Prior to TERA, he worked for 15 years for Environmental Protection Agency, holding several leadership roles and winning 4 bronze medals for joint efforts on specific key projects. Dr. Dourson received the SOT 2003 Lehman Award and the International Society of Regulatory Toxicology and Pharmacology’s 2009 International Achievement award. Two of his publications have won paper of the year awards from the SOT’s Risk Assessment Specialty Section (RASS). He has been elected to multiple officer positions including President of the American Board of Toxicology, President of the SOT RASS, Vice President-Elect of the SOT Mixtures Specialty Section, and Secretary of the Society for Risk Analysis. He is a media resource specialist in risk assessment for the SOT, a member of the editorial board of two journals, and vice chair of the NSF International Health Advisory Board.

Nanotoxicology Specialty Section

Annette Santamaria, Ph.D., M.P.H., DABT, President

Dr. Santamaria is a Senior Manager in the Health Sciences Practice of ENVIRON International Corporation in Houston, Texas. She is a board-certified toxicologist and has extensive experience evaluating the health risks associated with exposure to a variety of consumer products, pharmaceuticals, medical devices, food additives, personal care products, and industrial chemicals. She developed the Nanotoxicology Specialty Section and currently serves as the section’s president. Dr. Santamaria has written a book chapter with Dr. Christie Sayes entitled “Toxicological Studies with Nanomaterials” for the book, “Risk Governance of Nanotechnology”. She has critically reviewed literature on nanometals (e.g., TiO2, ZnO, Silver) to evaluate the toxicity and potential for dermal penetration of these nanoparticles. She has also reviewed literature to evaluate the association between exposure to manganese and neurotoxicity, and has prepared comments on a variety of draft risk assessments that were conducted to develop guidance and regulatory levels for ambient manganese levels.

Nanotoxicology Specialty Section

David B. Warheit, Ph.D., DABT, ATS, Vice President

Dr. Warheit is a Research Fellow at DuPont Haskell Global Centers in Newark, DE. He received his B.A. from the University of Michigan and his Ph.D. from Wayne State University School of Medicine. He was awarded an NIH Postdoctoral Fellowship and a Parker Francis Pulmonary Fellowship, both of which he took to NIEHS to study mechanisms of asbestos-related lung disease. In 1984, he moved to DuPont Haskell Laboratory. He has attained Diplomate status from the Academy of Toxicological Sciences (2000) and the American Board of Toxicology (1988) and served on NIH study sections. He has participated in several working groups, including IARC and the National Academy of Sciences, as well as several journal editorial boards, including current Associate Editor for Inhalation Toxicology and Toxicological Sciences. He is a past president of the Inhalation and Respiratory Specialty Section and a current member of the SOT Program Committee.

Neurotoxicology Specialty Section

Susan L. Schantz, Ph.D., President

Dr. Schantz is a Professor of Environmental Toxicology at the University of Illinois, where she directs both the Interdisciplinary Environmental Toxicology Program and the NIEHS-funded Toxicology Training Grant. She received her B.A. in Psychology and her Ph.D. in Environmental Toxicology from the University of Wisconsin-Madison. She later did postdoctoral research in the Psychology Department at Wayne State University. Dr. Schantz has an active research program funded by NIEHS, NIA, USEPA, and ATSDR, which focuses on understanding the nervous system effects of several widespread environmental contaminants including PCBs, PBDEs, bisphenol A and phthalates, and includes epidemiological studies of exposed human populations as well as parallel laboratory studies in animal models. She is currently a member of the Science Advisory Board for the International Joint Commission and serves an associate editor for Environmental Health Perspectives. She has been active in the Society of Toxicology for over 20 years.

Neurotoxicology Specialty Section

Stephen Lasley, Ph.D., Vice President

Dr. Lasley received his Ph.D. from the University of Louisville in 1979, and was a postdoctoral fellow in Environmental Health at the University of Cincinnati College of Medicine from 1979-1982. He joined the Dept. of Cancer Biology and Pharmacology at the University of Illinois College of Medicine in 1986. He is Course Director of the Medical Pharmacology course, chairs the local IACUC, has served on numerous grant review panels for NIH/NIEHS, and is an Associate Editor for NeuroToxicology. An SOT member since 1986, he was Councilor for the Neurotoxicology Specialty Section (2004-2006), and during that time, Chair of the subcommittee to review nominations for the NTSS Distinguished Investigator Award. Dr. Lasley has served as Director of the SOT Placement Service (1996-97) and Chair of the SOT Animals in Research Committee (2004-05). His research interests concern the neurotoxicity resulting from chronic exposure to heavy metals and the effects on the processes of neurotransmission underlying synaptic plasticity.

Neurotoxicology Specialty Section

Marion Ehrich, Ph.D., DABT, ATS, Past President

Dr. Marion Ehrich is a professor at Virginia-Maryland Regional College of Veterinary Medicine in Blacksburg, VA. In addition to the teaching of pharmacology and toxicology to veterinary and graduate students, her professional responsibilities include service in the Veterinary Medical Teaching Hospital Pharmacy and in the Toxicology Diagnostic Laboratory. Dr. Ehrich has a B.S. in pharmacy from South Dakota State University, a M.S. in pharmacology/toxicology from the University of Chicago, and a Ph.D. in pharmacology/toxicology from the University of Connecticut at Storrs. She has been teaching at VMRCVM since 1980, the year in which she became a member of the Society of Toxicology and a Diplomate of the American Board of Toxicology. She was elected a fellow of the Academy of Toxicological Sciences in 1999. Dr. Ehrich’s primary research activities are associated with the comparative neurotoxicities of antiesterase pesticides, with both in vivo and in vitro models used for study. Dr. Ehrich was the 2003-2004 President of the Society of Toxicology.

Occupational and Public Health Specialty Section

Angela J. Harris, Ph.D. DABT, Past President

Dr. Angela J. Harris is Senior Toxicologist and Manager of Toxicology for the Center for Toxicology and Environmental Health, LLC. Dr. Harris performs toxicological evaluations and human health risk assessments. She provides toxicological support during emergency responses following the release of hazardous materials and has been involved in the initial response or subsequent toxicological evaluation in a number of train derailments, chemical explosions, and disaster such as the World Trade Center collapse and Hurricanes Katrina and Rita. Dr. Harris also participates in community meetings and interacts with emergency care personnel to distribute pertinent toxicological information to affected communities. She acts as a consultant in general toxicology and in litigation involving toxicological issues.

Dr. Harris earned a Ph.D. in interdisciplinary Toxicology from the University of Arkansas School for Medical Sciences. Prior to coming to CTEH, Dr. Harris was a toxicologist at the National Center for Toxicological Research (NCTR), a research branch of the Food and Drug Administration for nine years where she conducted research in genetic toxicology, hepatotoxicology, molecular toxicology and genomics. In addition, Dr. Harris worked as a molecular biologist for several biotechnology companies on projects ranging from the cloning and genetic manipulation of bacterial and human genes and the expression of novel genes in bacterial, inset and mammalian cells for drug development purposes. Dr. Harris has more than 25 years of experience in drug development and toxicology.

Dr. Harris is a member of the South Central Chapter of the Society of Toxicology and the American Academy of Clinical Toxicology. She is currently Vice-President Elect for the Occupational and Public health Specialty Section of the SOT. She is also a member of the Scientific Advisory Board for Connexios Life Sciences in Bangalore, India and a Diplomate of the American Board of Toxicology.

Regulatory and Safety Evaluation Specialty Section

Frank D. Sistare, Ph.D., Past President

Dr. Sistare has served since 2003 as Executive Director of the Department of Laboratory Sciences and Investigative Toxicology within Safety Assessment at Merck Research Laboratories. The Department is responsible for genetic toxicology assessments and molecular carcinogenesis investigations; for bioanalytical toxicokinetic support; for implementing directed investigative toxicology research solutions and support for safety lead optimization; for incorporating new in vitro and in vivo model systems and technologies including genomics, proteomics, metabonomics; and for providing clinical pathology, immunology, and biomarker development support to Safety Assessment. He served previously for 15 years with the laboratory research component of the Food and Drug Administration’s Center for Drug Evaluation and Research where he served or chaired numerous FDA regulatory committees and working groups. Dr. Sistare is a retired Captain from the Public Health Service Commissioned Corps and has received several PHS Unit Commendations, as well as PHS Meritorious Service, Commendation, and Achievement Awards, and CDER and FDA awards for excellence in laboratory research. He earned his BS in Pharmacy from the University of Rhode Island, his Ph.D. in Pharmacology at the University of Virginia, and was awarded a postdoctoral PRAT Fellowship at the National Institutes of Health. He currently serves as President of the Regulatory and Safety Evaluation Specialty Section of the Society of Toxicology, as Co-Director of the Critical Path Institute's Predictive Safety Testing Consortium (PSTC), and as Co-Chairperson to the PSTC Nephrotoxicity Biomarker Working Group.

Reproductive and Developmental Toxicology Specialty Section

Mark E. Hurtt, Ph.D., President

Dr. Hurtt is Head of Global Reproductive and Developmental Toxicology at Pfizer Global Research and Development, Groton Laboratory He completed his formal education at the University of Cincinnati College of Medicine. He completed a post-doctoral fellowship at the Chemical Industry Institute of Toxicology in Research Triangle Park, North Carolina. Following a brief stay at Warner-Lambert in Ann Arbor, Michigan, Dr. Hurtt joined the DuPont Company. He held various roles over his 11 years at Haskell Laboratory for Toxicology and Industrial Medicine in Newark, Delaware, prior to joining Pfizer. Currently, Dr. Hurtt has overall responsibility for developmental and reproductive toxicology testing and consulting offerings as well as an investigative laboratory.

Reproductive and Developmental Toxicology Specialty Section

Alan M. Hoberman, Ph.D., DABT, Fellow ATS, Vice President

Dr. Hoberman was trained in anatomy and embryology at the University of Virginia and in toxicology at the University of Arkansas and the National Center for Toxicological Research. He worked in the field of toxicology for over 34 years and specialized in reproductive and developmental toxicology for over 31 years. As a Diplomate of the American Board of Toxicology (1988), Dr. Hoberman has over 70 publications and 188 presentations of abstracts and lectures in the fields of reproductive and developmental toxicology, neurotoxicology, inhalation toxicology, photobiology and regulatory toxicology. His current research interests include the development of the immune response and the assessment of compounds in young animals. Dr. Hoberman’s level of expertise in all aspects of preclinical toxicology and chemical safety testing has proven invaluable in the overall approval process to bring new entities to market.

Reproductive and Developmental Toxicology Specialty Section

Lori Dostal, Ph.D., DABT, Past President

Dr. Lori Dostal is a drug development consultant with Aptuit Consulting, Inc providing preclinical support for small biotech as well as large pharmaceutical companies for the development of new medicines. Previously she worked at Parke-Davis/Warner Lambert and Pfizer in Ann Arbor, Michigan where she was involved in Reproductive and Developmental Toxicology, as well as drug discovery and development teams. Dr. Dostal is recognized as an expert in reproductive and developmental toxicology, and contributed to the nonclinical development of Lipitor® and Lyrica®. Dr. Dostal is actively involved in the Society of Toxicology currently as the President of the Reproductive and Developmental Toxicology Specialty Section, and she has served on the Program Committee and the SOT Nominating Committee.

Dr. Dostal received a BS degree from the University of Michigan and PhD in Pharmacology from the University of North Carolina at Chapel Hill. She did postdoctoral fellowships at NIEHS and the National Toxicology Program in Research Triangle Park, North Carolina. Dr. Dostal is also certified in General Toxicology by the American Board of Toxicology.

Risk Assessment Specialty Section

Edward V. Ohanian, Ph.D., President

Dr. Ohanian is the Director of the Health and Ecological Criteria Division, Office of Water, United States Environmental Protection Agency (USEPA), in Washington, D.C. The Division is responsible for conducting human and ecological risk assessments as required under both the Safe Drinking Water Act and Clean Water Act. Recently, he has been appointed the Chairman of the USEPA Risk Assessment Forum. He also serves as an Adjunct Associate Professor with the School of Public Health and Health Services at George Washington University Medical Center. As a Co-Founder and Co-Chairman of the Federal-State Toxicology and Risk Analysis Committee, he has been instrumental in fostering cooperation and consistency regarding improved risk assessment and management methodologies. Recently, he was the co-editor of the book entitled “Toxicokinetics and Risk Assessment.” His elected and appointed positions at SOT have included: Committee on Public Communications; Councilor, Epidemiology Specialty Section, and Risk Assessment Specialty Section; and President, Risk Assessment Specialty Section. Dr. Ohanian is the recipient of the 2010 Arnold J. Lehman Award for his contributions to risk assessment and regulations of contaminants.

Toxicologic and Exploratory Pathology Specialty Section

Charles W. Qualls, Jr., D.V.M., Ph.D., DACVP, President

Dr. Qualls is Executive Director of Investigative Toxicology at Amgen where he leads a group of experts that focuses on issue resolution and predictive toxicology. Prior to coming to Amgen Dr. Qualls served in various positions at Glaxo Wellcome/GlaxoSmithKline including Pathologist, Project Director, and Head of Molecular and Ultrastructural Pathology. Dr. Qualls has spent the majority of his career in academia. While on faculty in the Department of Pathology in the College of Veterinary Medicine at Oklahoma State University from 1982 to 1999 he was major advisor to 8 PhD students and was on 18 graduate committees. His research focused on echo toxicology with major funding from the U.S. Army, U.S. Air Force and U.S. Environmental Protection Agency.

Toxicologic and Exploratory Pathology Specialty Section

Doug Wolf, D.V.M., Ph.D., Vice President-Elect

Dr. Wolf received his D.V.M. from the University of Missouri in 1981. After 6 years in clinical practice, he completed his pathology residency and Ph.D. in Veterinary Pathology at Purdue University in 1991. Dr. Wolf was a staff scientist for 6 years at the Chemical Industry Institute of Toxicology (CIIT), studying chemical carcinogenesis. From 1997-2007, he was a principal investigator at the National Health and Environmental Effects Research Laboratory (NHEERL) of the U.S. EPA, where he continued his work in carcinogenesis and molecular pathology. Currently, he is an Assistant Laboratory Director for NHEERL. Dr. Wolf has authored or coauthored over 125 journal articles, book chapters, and technical reports and has presented his work at numerous scientific meetings. He is an adjunct faculty member at North Carolina State University; University of North Carolina; and the Virginia Polytechnic Institute. Dr. Wolf was elected a Fellow of the International Academy of Toxicologic Pathologists in 2004 and a Fellow of the Academy of Toxicological Sciences in 2007.